PL3474904T3 - Otrzymywanie przeciwciał monoklonalnych znakowanych 212pb - Google Patents
Otrzymywanie przeciwciał monoklonalnych znakowanych 212pbInfo
- Publication number
- PL3474904T3 PL3474904T3 PL17732126.2T PL17732126T PL3474904T3 PL 3474904 T3 PL3474904 T3 PL 3474904T3 PL 17732126 T PL17732126 T PL 17732126T PL 3474904 T3 PL3474904 T3 PL 3474904T3
- Authority
- PL
- Poland
- Prior art keywords
- obtaining
- monoclonal antibodies
- labelled monoclonal
- labelled
- antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/008—Peptides; Proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16176263 | 2016-06-24 | ||
| PCT/EP2017/065508 WO2017220767A1 (en) | 2016-06-24 | 2017-06-23 | Preparation of 212pb labeled monoclonal antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3474904T3 true PL3474904T3 (pl) | 2024-12-16 |
Family
ID=56263569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17732126.2T PL3474904T3 (pl) | 2016-06-24 | 2017-06-23 | Otrzymywanie przeciwciał monoklonalnych znakowanych 212pb |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11306038B2 (pl) |
| EP (1) | EP3474904B1 (pl) |
| JP (1) | JP7176958B2 (pl) |
| CN (1) | CN109310789B (pl) |
| AU (1) | AU2017281649B2 (pl) |
| CA (1) | CA3026599A1 (pl) |
| ES (1) | ES2991349T3 (pl) |
| IL (1) | IL263808B2 (pl) |
| MX (1) | MX2018016121A (pl) |
| PL (1) | PL3474904T3 (pl) |
| WO (1) | WO2017220767A1 (pl) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| CA2935960C (en) | 2014-01-08 | 2023-01-10 | Bart Lipkens | Acoustophoresis device with dual acoustophoretic chamber |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| SG11202003907WA (en) | 2017-12-14 | 2020-05-28 | Flodesign Sonics Inc | Acoustic transducer drive and controller |
| CN114902350A (zh) | 2019-12-05 | 2022-08-12 | 塞控斯公司 | 生产高纯度212Pb |
| EP4385045B1 (en) | 2021-08-11 | 2025-10-01 | Nrg Pallas B.V. | System and method of the production and isolation of charged radionuclides |
| EP4482533A4 (en) * | 2022-02-24 | 2026-02-25 | Alpha Tau Medical Ltd | Alpha Convection-Enhanced Diffusion Radiotherapy |
| JP7816003B2 (ja) * | 2022-06-06 | 2026-02-18 | Jfeエンジニアリング株式会社 | 放射性物質の標識方法 |
| US20240091705A1 (en) * | 2022-09-16 | 2024-03-21 | Viewpoint Molecular Targeting, Inc. | Removal of free-unlabeled cationic and anionic solution phase radionuclides from radiopharmaceuticals using solid-phase extraction techniques |
| WO2025163082A1 (en) | 2024-01-31 | 2025-08-07 | Molecular Partners Ag | Dll3-specific binding constructs and their use in radiotherapy |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO312708B1 (no) * | 2000-02-21 | 2002-06-24 | Anticancer Therapeutic Inv Sa | Radioaktive liposomer til terapi |
| DE10040771A1 (de) | 2000-08-21 | 2002-03-14 | Altmann Therapie Gmbh & Co Kg | Neue, 224Ra enthaltende, radiotherapeutisch wirksame Formulierungen und Verfahren zu ihrer Herstellung |
| DE10347459B3 (de) * | 2003-10-13 | 2005-05-25 | Actinium Pharmaceuticals, Inc. | Radium-Target sowie Verfahren zu seiner Herstellung |
| HUE025945T2 (en) * | 2005-02-15 | 2016-07-28 | Univ Duke | Anti-CD19 antibodies and their applications in oncology |
| WO2012032043A1 (en) * | 2010-09-07 | 2012-03-15 | Areva Med Llc | 212 pb imaging |
| US9433690B1 (en) | 2015-02-26 | 2016-09-06 | Sciencons AS | Radiopharmaceutical solutions with advantageous properties |
| DK3261681T3 (da) * | 2015-02-26 | 2020-04-27 | Sciencons AS | Radiofarmaceutiske opløsninger med fordelagtige egenskaber |
| ES2657388T3 (es) * | 2015-02-26 | 2018-03-05 | Sciencons AS | Disoluciones radiofarmacéuticas con propiedades ventajosas |
-
2017
- 2017-06-23 CN CN201780038560.8A patent/CN109310789B/zh active Active
- 2017-06-23 MX MX2018016121A patent/MX2018016121A/es unknown
- 2017-06-23 CA CA3026599A patent/CA3026599A1/en active Pending
- 2017-06-23 US US16/307,811 patent/US11306038B2/en active Active
- 2017-06-23 WO PCT/EP2017/065508 patent/WO2017220767A1/en not_active Ceased
- 2017-06-23 AU AU2017281649A patent/AU2017281649B2/en active Active
- 2017-06-23 JP JP2018566836A patent/JP7176958B2/ja active Active
- 2017-06-23 IL IL263808A patent/IL263808B2/en unknown
- 2017-06-23 ES ES17732126T patent/ES2991349T3/es active Active
- 2017-06-23 PL PL17732126.2T patent/PL3474904T3/pl unknown
- 2017-06-23 EP EP17732126.2A patent/EP3474904B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN109310789B (zh) | 2021-12-03 |
| ES2991349T3 (es) | 2024-12-03 |
| JP2019523232A (ja) | 2019-08-22 |
| NZ749058A (en) | 2025-07-25 |
| EP3474904A1 (en) | 2019-05-01 |
| US20190194087A1 (en) | 2019-06-27 |
| IL263808B1 (en) | 2024-12-01 |
| US11306038B2 (en) | 2022-04-19 |
| CN109310789A (zh) | 2019-02-05 |
| AU2017281649B2 (en) | 2023-07-27 |
| CA3026599A1 (en) | 2017-12-28 |
| EP3474904B1 (en) | 2024-08-07 |
| IL263808A (en) | 2019-02-03 |
| WO2017220767A1 (en) | 2017-12-28 |
| MX2018016121A (es) | 2019-05-30 |
| IL263808B2 (en) | 2025-04-01 |
| JP7176958B2 (ja) | 2022-11-22 |
| AU2017281649A1 (en) | 2019-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272227A (en) | Anti-tigit antibodies | |
| IL269405A (en) | Anti-sirp alpha antibodies | |
| IL272274A (en) | B7-h4 antibodies and methods of use thereof | |
| DK3625259T3 (da) | Anti-sirpalpha-antistoffer | |
| EP3661558A4 (en) | ANTI-IL1RAP ANTIBODIES | |
| HUE060019T2 (hu) | Anti-LAG3 antitestek | |
| EP3532489A4 (en) | ANTI-TL1A NEUTRALIZING MONOCLONAL ANTIBODIES | |
| EP3569709A4 (en) | ANTI-GPC3 ANTIBODIES | |
| DK3455257T3 (da) | Anti-pd-l1-antistoffer | |
| EP3387442A4 (en) | HUMANIZED ANTI-CD73 ANTIBODIES | |
| HUE051700T2 (hu) | Anti-PD-1 antitestek | |
| EP3691447A4 (en) | ANTI-TRANSTHYRETINE ANTIBODY | |
| EP3481869A4 (en) | ANTI-CD73 ANTIBODIES | |
| DK3332006T5 (da) | Hidtil ukendte anti-PD-L1-antistoffer | |
| DK3441086T3 (da) | Monoklonalt anti-PD-1-antistof | |
| KR20180085002A (ko) | 인간화된 항-cll-1 항체 | |
| IL256097A (en) | Antibody epitope | |
| EP3507307A4 (en) | BISPECIFIC ANTIBODIES | |
| DK3606961T3 (da) | Garp-tgf-beta-antistoffer | |
| DK3452513T3 (da) | Humaniserede anti-il-ir3-antistoffer | |
| DK3649152T3 (da) | ROR1-antistoffer | |
| EP3589648A4 (en) | MONOCLONAL ANTI-RSV ANTIBODY FORMULATION | |
| IL263808A (en) | Preparation of 212pb labeled monoclonal antibodies | |
| HUE061076T2 (hu) | Humanizált anti-C1s ellenanyagok alkalmazási eljárások | |
| EP3532034A4 (en) | ANTI-APOE ANTIBODY |